GlcNAc phosphotransferase of the lysosomal targeting pathway
AssigneeGenzyme Corporation
InventorWilliam M. Canfield
Life of this patent
Estimating the term…
Abstract
The present invention provides nucleotide and amino sequences of the lysosomal targeting pathway enzyme GlcNAc-phosphotransferase, methods of producing and methods of purifying this enzyme.
Claims2
A pharmaceutical composition suitable for the treatment of a human patient having Pompe disease comprising recombinant human alpha-glucosidase, wherein said composition has an average of at least 5 mannose-6-phosphate residues per molecule human recombinant alpha-glucosidase and a pharmaceutically acceptable carrier.
A pharmaceutical composition suitable for the treatment of a human patient having Pompe disease comprising recombinant human alpha-glucosidase, wherein said composition has an average of about at least 6% bis-phosphorylated oligosaccharides per molecule of human recombinant alpha glucosidase and a pharmaceutically effective carrier.
Dependencies are inferred from the claim text.